Silence Therapeutics has unveiled additional data from a mid-stage trial of its siRNA therapy candidate in certain people at risk of heart episodes, setting the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.